水会锋

郑州大学附属洛阳中心医院中西医结合肿瘤科，河南洛阳471000

顺铂联合卡培他滨治疗晚期胃癌腹腔积液的疗效及安全性研究

水会锋

郑州大学附属洛阳中心医院中西医结合肿瘤科，河南洛阳471000

目的探讨顺铂联合卡培他滨治疗晚期胃癌腹腔积液的疗效及安全性。方法选择我院2014年2月～2015年2月期间收治的98例晚期胃癌腹腔积液患者作为研究对象，随机将其分为对照组和观察组。对照组患者单纯采用顺铂进行化疗，观察组患者采用顺铂联合卡培他滨进行治疗。对比分析两组患者临床治疗效果及不良反应发生情况。结果观察组患者治疗1个疗程后和2个疗程后治疗总有效率均明显高于对照组，差异有统计学意义（P＜0.05）。观察组患者在治疗期间不良反应发生率稍高于对照组，但差异无统计学意义（P＞0.05）。结论顺铂联合卡培他滨治疗晚期胃癌腹腔积液效果显著，且不良反应少，是一种较为安全且高效的治疗手段，值得在临床上推广使用。

顺铂曰卡培他滨曰化疗曰胃癌腹腔积液曰热疗

［Abstract］Objective To explore the curative effects and safety of cisplatin combined with capecitabine in the patients with advanced gastric cancer-induced seroperitoneum.Methods 98 patients with advanced gastric cancer-induced seroperitoneum who were admitted to our hospital from February 2014 to February 2015 were selected as research subjects.They were randomly assigned to the control group and the observation group.The control group was given cisplatin alone for the chemotherapy，and the observation group was given cisplatin combined with capecitabine for the chemotherapy.Clinical curative effects and adverse reactions were compared and analyzed between the two groups of patients.Results The total effective rates in the observation group after 1 course of treatment and 2 courses of treatment were both significantly higher than those in the control group，and the differences were statistically significant（P＜0.05）.The incidence rate of adverse reactions during the treatment in the observation group was slightly higher than that in the control group，and the difference was not statistically significant（P＞0.05）.Conclusion Cisplatin combined with capecitabine is significantly effective in the treatment for the patients with advanced gastric cancer-induced seroperitoneum，with few adverse reactions，which is a safe and effective treatment method and is worthy of clinical promotion and application.

［Key words］Cisplatin；Capecitabine；Chemotherapy；Gastric cancer-induced seroperitoneum；Thermal therapy

近年来胃癌的发生率呈现逐年上升的趋势，胃癌的防治成为现今医学工作者的研究重点。在我国由于人们健康保健意识较差再加之医学诊断水平不高，导致了胃癌患者在发现时已经进入了晚期，错过了疾病治疗的最佳时期。大量的调查研究表明，晚期胃癌腹腔积液患者对静脉联合化疗不耐受，因此，积极探索更加有效的控制腹腔积液的手段显得尤为迫切［1］。……